SFX by Ex Libris Inc.

Title:	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Source:	Acs Medicinal Chemistry Letters [1948-5875] Popovici Muller, Janeta yr:2012

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Wang, F. "Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation." Science 340.ARRAY(0x2b9d730) (2013): 622-6.
description	2.	Levine, Alan L. "IDH1 Mutations Disrupt Blood, Brain, and Barriers." Cancer cell 22.3 (2012): 285-7.
description	3.	Connolly, Ricardo S. "IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate." Neurosurgery 66.4 (2010): -1.
description	4.	Rohle, D. "An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells." Science 340.6132 (2013): 626-30.
description	5.	Wilson, Wyndham H. "Reevaluating the Accelerated Approval Process for Oncology Drugs." Clinical cancer research 19.11 (2013): 1078-432.
description	6.	Smeitink, Jan n. "Metabolism, gliomas, and IDH1." New England Journal of Medicine, The 362.12 (2010): 1144-1145.
description	7.	Zhu, H. "IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced." PLoS One 12.1 (2017).
description	8.	Chi, Andrew S. "BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults." Journal of clinical oncology 31.14 (2013): -6.
description	9.	EVANS, J. "MR Spectroscopy May Track Glioma's Presence." Clinical Neurology News 8.2 (2012): 10-10.
description	10.	Hemminki, K. "Subsequent leukaemia in autoimmune disease patients." British journal of haematology 161.5 (2013): 677-687.
description	11.	Cohen, Adam L. "IDH1 and IDH2 Mutations in Gliomas." Current neurology and neuroscience reports 13.5 (2013): 345-345.
description	12.	Godley, Lucy A. "Profiles in leukemia." The New England journal of medicine 366.12 (2012): 1152-1153.
description	13.	Blau, Eckhard W. "Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts." Blood 118.20 (2011): 5583-5592.
description	14.	McCammon, Mark T. "Multiple cellular consequences of isocitrate dehydrogenase isozyme dysfunction." Archives of biochemistry and biophysics 419.2 (2003): 222-233.
description	15.	Gaal, J. "Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas." The Journal of clinical endocrinology and metabolism 95.3 (2009): 1274-1278.
description	16.	Kaelin, William G. "SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling." Cancer Cell 16.3 (2009): 180-2.
description	17.	Beard, C. "Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells." Genesis 44.1 (2006): 23-28.
description	18.	Von, Christian A. "The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations." Brain pathology 21.1 (2011): 74-87.
description	19.	Brismar, T. "Effect of metabolic inhibitors on membrane potential and ion conductance of rat astrocytes." Cellular and molecular neurobiology 17.4 (1997): 367-377.
description	20.	Wick, W. "NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide." Journal of clinical oncology 27.35 (2009): 5874-5880.